abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Glenohumeral Osteoarthritis: The Role for Orthobiologic Therapies: Platelet-Rich Plasma and Cell Therapies


JBJS Rev. 2020 Feb;8(2):e0075. doi: 10.2106/JBJS.RVW.19.00075.

Luciano A Rossi 1Nicolás S Piuzzi 1 2Shane A Shapiro 3 4

Author Information

1 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

2 Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, Ohio.

3 Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, Florida.

4 Mayo Clinic Center for Regenerative Medicine, Rochester, Minnesota.


The glenohumeral (GH) joint ranks third on the list of the large joints that are most commonly affected by osteoarthritis, after the knee and the hip. General nonsurgical modalities, including changes in daily activities, physical therapy, pharmacotherapy, and corticosteroid injections, constitute the mainstay of treatment. Most of these options, however, have shown moderate and short-term effectiveness. Arthroplasty techniques have proven to be successful for elderly patients. Nevertheless, replacement options are not optimal for younger patients because their functional demands are higher and prostheses have a finite life span. This has led to the search for new nonoperative treatment options to target this subgroup of patients. It has been suggested that orthobiologic therapies, including platelet-rich plasma (PRP) and cell therapies, present great promise and opportunity for the treatment of GH osteoarthritis. Despite the promising results that have been shown by cell therapies and PRP for treating degenerative joint conditions, additional studies are needed to provide more definitive conclusions.